136 related articles for article (PubMed ID: 1673944)
21. Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.
Mirkin S; Pinkerton JV; Kagan R; Thompson JR; Pan K; Pickar JH; Komm BS; Archer DF
J Womens Health (Larchmt); 2016 May; 25(5):431-42. PubMed ID: 27058301
[TBL] [Abstract][Full Text] [Related]
22. Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women.
Grey A; Cundy T; Evans M; Reid I
Clin Endocrinol (Oxf); 1996 Mar; 44(3):293-6. PubMed ID: 8729524
[TBL] [Abstract][Full Text] [Related]
23. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
24. The effect of low-dose conjugated equine estrogens and cyclic MPA on bone density.
Gass M; Liu J; Rebar RW
Maturitas; 2002 Feb; 41(2):143-7. PubMed ID: 11836045
[TBL] [Abstract][Full Text] [Related]
25. Medroxyprogesterone and bone mineral density response to oestrogen.
Kanis JA
Clin Endocrinol (Oxf); 1996 Mar; 44(3):297-8. PubMed ID: 8729525
[No Abstract] [Full Text] [Related]
26. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group.
Woodruff JD; Pickar JH
Am J Obstet Gynecol; 1994 May; 170(5 Pt 1):1213-23. PubMed ID: 8178840
[TBL] [Abstract][Full Text] [Related]
27. The effect of hormone replacement on physical performance in community-dwelling elderly women.
Greenspan SL; Resnick NM; Parker RA
Am J Med; 2005 Nov; 118(11):1232-9. PubMed ID: 16271907
[TBL] [Abstract][Full Text] [Related]
28. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss.
Lukert BP; Johnson BE; Robinson RG
J Bone Miner Res; 1992 Sep; 7(9):1063-9. PubMed ID: 1329440
[TBL] [Abstract][Full Text] [Related]
29. Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women.
Gibbons WE; Moyer DL; Lobo RA; Roy S; Mishell DR
Am J Obstet Gynecol; 1986 Feb; 154(2):456-61. PubMed ID: 3004222
[TBL] [Abstract][Full Text] [Related]
30. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.
Agnusdei D; Gennari C; Bufalino L
Osteoporos Int; 1995; 5(6):462-6. PubMed ID: 8695969
[TBL] [Abstract][Full Text] [Related]
31. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Mirkin S; Komm BS; Pan K; Chines AA
Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
[TBL] [Abstract][Full Text] [Related]
32. Effect of sequential and daily continuous hormone replacement therapy on indexes of mineral metabolism.
el-Hajj Fuleihan G; Brown EM; Curtis K; Berger MJ; Berger BM; Gleason R; LeBoff MS
Arch Intern Med; 1992 Sep; 152(9):1904-9. PubMed ID: 1325762
[TBL] [Abstract][Full Text] [Related]
33. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women.
Lobo RA; McCormick W; Singer F; Roy S
Obstet Gynecol; 1984 Jan; 63(1):1-5. PubMed ID: 6318170
[TBL] [Abstract][Full Text] [Related]
34. [Plasma estrogen levels in postmenopausal women treated with estrogens alone or combined with medroxyprogesterone acetate in the same tablet].
Gadán A
Rev Chil Obstet Ginecol; 1992; 57(4):283-6. PubMed ID: 1342454
[TBL] [Abstract][Full Text] [Related]
35. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
Palomba S; Orio F; Russo T; Falbo A; Tolino A; Manguso F; Nunziata V; Mastrantonio P; Lombardi G; Zullo F
Osteoporos Int; 2005 Aug; 16(8):943-52. PubMed ID: 15739035
[TBL] [Abstract][Full Text] [Related]
36. Bazedoxifene/conjugated estrogens combination for the treatment of the vasomotor symptoms associated with menopause and for prevention of osteoporosis in postmenopausal women.
Palacios S; Mejía Ríos A
Drugs Today (Barc); 2015 Feb; 51(2):107-16. PubMed ID: 25756066
[TBL] [Abstract][Full Text] [Related]
37. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
Greenspan SL; Emkey RD; Bone HG; Weiss SR; Bell NH; Downs RW; McKeever C; Miller SS; Davidson M; Bolognese MA; Mulloy AL; Heyden N; Wu M; Kaur A; Lombardi A
Ann Intern Med; 2002 Dec; 137(11):875-83. PubMed ID: 12458987
[TBL] [Abstract][Full Text] [Related]
38. Effects of estrogen and progestin on aortic size and compliance in postmenopausal women.
Giraud GD; Morton MJ; Wilson RA; Burry KA; Speroff L
Am J Obstet Gynecol; 1996 Jun; 174(6):1708-17; discussion 1717-8. PubMed ID: 8678131
[TBL] [Abstract][Full Text] [Related]
39. Hormones and bone health in postmenopausal women.
Lindsay R
Endocrine; 2004 Aug; 24(3):223-30. PubMed ID: 15542889
[TBL] [Abstract][Full Text] [Related]
40. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss.
Mizunuma H; Shiraki M; Shintani M; Gorai I; Makita K; Itoga S; Mochizuki Y; Mogi H; Iwaoki Y; Kosha S; Yasui T; Ishihara O; Kurabayashi T; Kasuga Y; Hayashi K
J Bone Miner Metab; 2006; 24(1):11-5. PubMed ID: 16369892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
